Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-4.54 Insider Own0.10% Shs Outstand55.80M Perf Week-10.02%
Market Cap8.87B Forward P/E- EPS next Y-9.23 Insider Trans- Shs Float2.90M Perf Month-4.25%
Income-240.80M PEG- EPS next Q-2.33 Inst Own68.60% Short Float40.01% Perf Quarter-14.97%
Sales323.70M P/S27.41 EPS this Y43.60% Inst Trans-0.44% Short Ratio3.43 Perf Half Y28.80%
Book/sh22.58 P/B7.04 EPS next Y-2.00% ROA-17.80% Target Price206.80 Perf Year123.92%
Cash/sh24.54 P/C6.48 EPS next 5Y- ROE-24.50% 52W Range65.58 - 220.10 Perf YTD62.74%
Dividend- P/FCF- EPS past 5Y- ROI-11.70% 52W High-27.75% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin95.10% 52W Low142.48% ATR8.50
Employees900 Current Ratio8.10 Sales Q/Q- Oper. Margin-81.20% RSI (14)38.70 Volatility4.90% 4.79%
OptionableYes Debt/Eq0.17 EPS Q/Q-92.00% Profit Margin-75.20% Rel Volume0.78 Prev Close159.03
ShortableYes LT Debt/Eq0.17 EarningsAug 08 Payout- Avg Volume338.06K Price159.03
Recom1.70 SMA20-7.95% SMA50-8.29% SMA20010.51% Volume0 Change0.00%
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Mar-01-18Reiterated Maxim Group Buy $144 → $160
Nov-14-17Downgrade Robert W. Baird Outperform → Neutral $58 → $83
Sep-28-17Reiterated Maxim Group Buy $77 → $120
Aug-07-17Initiated Ladenburg Thalmann Buy $81
Jul-06-17Reiterated Maxim Group Buy $57 → $73
Jul-05-17Reiterated Maxim Group Buy $52 → $57
Sep-22-16Initiated Maxim Group Buy $41
Feb-29-16Initiated Robert W. Baird Outperform $44
Feb-29-16Initiated Morgan Stanley Overweight
Feb-29-16Initiated Goldman Buy $33
Aug-09-18 05:11AM  BRIEF-Beigene Initiates New Phase 3 Trial Of Anti-Pd-1 Antibody Tislelizumab Combined With Chemotherapy Reuters
05:08AM  BRIEF-Beigene Ltd Q2 Loss Per Share $0.22 Reuters
05:05AM  BeiGene Reports Second Quarter 2018 Financial Results GlobeNewswire
05:05AM  BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China PR Newswire
Aug-08-18 04:05PM  BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering GlobeNewswire
01:12AM  BeiGene's CEO on HK Debut, China Growth Strategy, Regulation Bloomberg Video
01:12AM  BeiGene's CEO on HK Debut, China Growth Strategy, Regulation Bloomberg
Aug-07-18 11:32PM  China Tower, BeiGene Make Trading Debut in Hong Kong Bloomberg Video
11:32PM  China Tower, BeiGene Make Trading Debut in Hong Kong Bloomberg
10:32PM  BeiGene founder on the timing of the company's IPO CNBC Videos
09:25PM  BRIEF-Shares Of Beigene Set To Open On Hong Kong Debut Flat At HK$108.00 Reuters
06:00PM  Zero-Sales Biotechs May Damage Your Financial Health Bloomberg
Aug-06-18 12:54AM  Hong Kong stocks can't escape US-China trade war's 'very long shadow' CNBC
Aug-04-18 06:03PM  Here's Why BeiGene Rose 23.4% in July Motley Fool
Aug-02-18 07:39AM  [$$] Chinese Cancer-Drugmaker Raises $900 Million in Hong Kong Listing The Wall Street Journal
06:57AM  BRIEF-Beigene Announces Pricing Of its Hong Kong IPO And Global Offering Reuters
06:44AM  BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering GlobeNewswire
12:51AM  Chinese biotech BeiGene raises $903 million in Hong Kong's first secondary listing under new rules - sources Reuters
12:45AM  Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources Reuters
Aug-01-18 02:08AM  HKEX chief welcomes secondary listings while China finalises CDRs Reuters
Jul-27-18 08:19AM  BRIEF-Beigene Anticipates That The Public Offering Price Will Be Between Hk$94.40 And Hk$111.60 Per Share, Or Between About $12.03 And $14.22 Per Reuters
07:08AM  BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering GlobeNewswire
Jul-24-18 04:30PM  BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
07:00AM  BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer GlobeNewswire
Jul-23-18 08:00AM  Today's Research Reports on Trending Tickers: Celgene and BeiGene ACCESSWIRE
Jul-22-18 04:30PM  BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkins Lymphoma GlobeNewswire
04:30PM  BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM) GlobeNewswire
Jul-20-18 04:47AM  BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited GlobeNewswire
Jul-03-18 10:45PM  3 Reasons BeiGene Needs to Be on Your Radar Motley Fool
04:05PM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-19-18 05:00AM  Chinas Getting Ready to Take On the Worlds Biggest Drugmakers Bloomberg
05:00AM  China Is Getting Ready to Take On the Worlds Biggest Drugmakers Bloomberg
Jun-15-18 02:00AM  BeiGene Provides Development Update and Presents Clinical Data on Zanubrutinib at the 23rd Congress of the European Hematology Association GlobeNewswire
Jun-06-18 07:00AM  BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
Jun-05-18 07:00AM  BeiGene to Present at the William Blair 2018 Growth Stock Conference GlobeNewswire
Jun-01-18 07:00AM  BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23rd Congress of the European Hematology Association GlobeNewswire
May-21-18 07:40AM  Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in China ACCESSWIRE
May-19-18 11:49AM  These Stocks Have Quadrupled in Just 1 Year Motley Fool
May-17-18 07:00AM  BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer GlobeNewswire
May-15-18 04:05PM  BeiGene to Present at the 2018 UBS Global Healthcare Conference GlobeNewswire
May-09-18 04:15PM  BeiGene Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 07:30AM  Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space? ACCESSWIRE
May-04-18 04:15PM  BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
May-01-18 07:00PM  BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd. GlobeNewswire
Apr-16-18 09:00AM  BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting GlobeNewswire
07:00AM  BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas GlobeNewswire
Apr-13-18 08:18AM  These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years Motley Fool
Apr-12-18 07:20AM  Wired News BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients ACCESSWIRE
Apr-10-18 07:00AM  BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma GlobeNewswire
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-03-18 07:00AM  BeiGene Appoints J. Samuel Su to its Board of Directors GlobeNewswire
Mar-20-18 08:20AM  Todays Research Reports on Trending Tickers: BeiGene and Exact Sciences ACCESSWIRE +5.23%
Mar-18-18 10:31AM  2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing? Motley Fool
Mar-13-18 07:45AM  Report: Exploring Fundamental Drivers Behind BeiGene, Snyder's-Lance, China Lodging Group, Amdocs, LG Display Co., and Acacia Communications New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-11-18 11:33AM  The Revolutionary New HIV Drug You've Probably Never Heard Of Motley Fool
Mar-05-18 07:00AM  BeiGene to Present at Upcoming Investor Conferences GlobeNewswire
12:39AM  China's Tasly to list biotech arm in $1 bln Hong Kong IPO - sources Reuters
Mar-02-18 08:15PM  Beigene Ltd (BGNE) CEO John Oyler Sold $14.4 million of Shares GuruFocus.com
Feb-28-18 04:05PM  BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-27-18 06:00PM  BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China GlobeNewswire
Feb-23-18 09:12AM  These 2 Biotech Stocks Are Soaring. Can They Keep It Up? Motley Fool
Feb-09-18 02:45PM  BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium GlobeNewswire
Feb-07-18 06:00AM  BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-05-18 06:00PM  BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China GlobeNewswire
05:30PM  BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium GlobeNewswire
04:03PM  Here's Why BeiGene, Ltd. Jumped 38.9% in January Motley Fool
Feb-02-18 07:40AM  Blog Exposure - BeiGene Commenced Dosing in Global Phase-3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with ESCC ACCESSWIRE
Jan-31-18 06:00AM  BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma GlobeNewswire +9.70%
Jan-27-18 04:29PM  Benzinga's Insider Buys Of The Week: BeiGene, Opko Health And More Benzinga
Jan-23-18 08:00AM  Celgene's Investments Are Soaring Motley Fool
Jan-22-18 04:05PM  BeiGene Announces Closing of $800 Million Public Offering GlobeNewswire
Jan-19-18 08:46AM  BeiGene (BGNE) Surges: Stock Moves 12.6% Higher Zacks
Jan-18-18 03:13PM  U.S. Investors Swarm China's Biotech Leader Barrons.com +12.60%
01:39PM  Why BeiGene Is Soaring 13.8% Today Motley Fool
10:45AM  Investors Cheer BeiGenes Secondary Offering 24/7 Wall St.
Jan-17-18 11:21PM  BeiGene Announces Pricing of $750 Million Public Offering GlobeNewswire
Jan-16-18 04:05PM  BeiGene Announces Proposed Public Offering GlobeNewswire
Jan-09-18 09:00AM  BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab GlobeNewswire
Jan-08-18 06:00AM  BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region GlobeNewswire
Jan-02-18 06:00AM  BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma GlobeNewswire
Dec-27-17 02:21PM  These Stocks Have Tripled Since Last Year Motley Fool
Dec-20-17 07:30AM  Blog Exposure - BeiGene Announced Initiation of Pivotal Trial of PARP Inhibitor Pamiparib in Chinese Patients with Ovarian Cancer ACCESSWIRE
Dec-18-17 06:00AM  BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer GlobeNewswire
Dec-11-17 10:24AM  Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says Benzinga
10:00AM  BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-09-17 12:15PM  BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkins Lymphoma at the 59th American Society of Hematology Annual Meeting GlobeNewswire
09:00AM  BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-17 07:15PM  Beigene Ltd (BGNE) CEO John Oyler Sold $13.5 million of Shares GuruFocus.com
Dec-04-17 04:05PM  BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting GlobeNewswire +16.67%
Nov-29-17 07:15PM  Beigene Ltd (BGNE) CEO John Oyler Sold $7.3 million of Shares GuruFocus.com
Nov-13-17 04:05PM  BeiGene Reports Third Quarter 2017 Financial Results GlobeNewswire
04:05PM  BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111 GlobeNewswire
Nov-01-17 09:00AM  BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-19-17 02:03AM  China biotech's 'coming out party' masks long road ahead Reuters
Sep-29-17 05:50AM  [$$] Celgene Invests in Acceleron, BeiGene Barrons.com +6.19%
Sep-28-17 09:00AM  BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO GlobeNewswire
Sep-21-17 04:15PM  BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-19-17 07:31AM  These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Motley Fool
Sep-12-17 01:34PM  [$$] Celgene Launch to Lift BeiGene Barrons.com
Sep-11-17 03:00AM  BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress GlobeNewswire
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorAug 02Buy108.005,814,100627,922,8005,250,491Aug 06 05:22 PM
OYLER JOHNChief Executive OfficerJul 16Sale164.122,550418,4970Jul 17 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 19Option Exercise6.5024,128156,83229,128Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 19Sale161.4629,1284,702,9850Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 16Option Exercise6.5010,87270,66815,872Mar 20 05:02 PM
Liang HowardCFO & Chief Strategy OfficerMar 16Sale157.0710,8721,707,6665,000Mar 20 05:02 PM
OYLER JOHNChief Executive OfficerMar 02Sale148.1325,3623,756,7840Mar 02 06:42 PM
OYLER JOHNChief Executive OfficerMar 01Sale143.0839,3005,623,20525,362Mar 02 06:42 PM
Li JiEVP and Gl. Head of Bus. Dev.Feb 28Option Exercise26.6510,000266,50010,000Mar 02 06:41 PM
OYLER JOHNChief Executive OfficerFeb 28Sale146.6934,3385,036,94364,662Mar 02 06:42 PM
Li JiEVP and Gl. Head of Bus. Dev.Feb 28Sale146.8810,0001,468,7600Mar 02 06:41 PM
BAKER BROS. ADVISORS LPDirectorJan 18Buy101.001,980,198199,999,9985,121,404Jan 22 05:03 PM
OYLER JOHNChief Executive OfficerDec 26Sale96.4620,1371,942,51599,000Dec 28 05:49 PM
Huang JaneCMO, HematologyDec 21Option Exercise29.511,00029,5101,000Dec 22 04:43 PM
Huang JaneCMO, HematologyDec 21Sale98.001,00098,0000Dec 22 04:43 PM
Huang JaneCMO, HematologyDec 13Option Exercise29.511,50044,2651,500Dec 15 04:05 PM
Huang JaneCMO, HematologyDec 13Sale94.251,500141,3810Dec 15 04:05 PM
OYLER JOHNChief Executive OfficerDec 08Sale95.5752,8175,047,758119,137Dec 08 05:57 PM
OYLER JOHNChief Executive OfficerDec 07Sale93.4059,7375,579,304171,954Dec 08 05:57 PM
OYLER JOHNChief Executive OfficerDec 06Sale92.2931,4462,902,224231,691Dec 08 05:57 PM
Huang JaneCMO, HematologyDec 04Sale86.001,10094,6000Dec 05 09:15 AM
OYLER JOHNChief Executive OfficerNov 29Sale82.9236,3403,013,458263,137Nov 29 05:33 PM
OYLER JOHNChief Executive OfficerNov 28Sale85.5232,9852,820,864299,477Nov 29 05:33 PM
OYLER JOHNChief Executive OfficerNov 27Sale86.7616,5811,438,582332,462Nov 29 05:33 PM
Huang JaneCMO, HematologyNov 20Sale87.001,00087,0001,100Nov 20 05:14 PM
Huang JaneCMO, HematologyNov 16Sale85.0060051,0002,100Nov 20 05:14 PM
OYLER JOHNChief Executive OfficerNov 15Sale80.2366,0685,300,508349,043Nov 15 08:12 PM
OYLER JOHNChief Executive OfficerNov 14Sale79.7459,8354,770,950415,111Nov 15 08:12 PM
Peterson Amy C.CMO, Immuno-oncologyNov 13Sale82.963,601298,7470Nov 15 08:11 PM
OYLER JOHNChief Executive OfficerNov 13Sale83.0625,0542,080,916474,946Nov 15 08:12 PM